# Study of CAD-1883 for Spinocerebellar Ataxia

> **NCT04301284** · PHASE2 · WITHDRAWN · sponsor: **Cadent Therapeutics**

## Conditions studied

- Spinocerebellar Ataxias
- Spinocerebellar Ataxia Type 1
- Spinocerebellar Ataxia Type 2
- Spinocerebellar Ataxia Type 3
- Spinocerebellar Ataxia Type 6
- Spinocerebellar Ataxia Type 7
- Spinocerebellar Ataxia Type 8
- Spinocerebellar Ataxia Type 10
- Spinocerebellar Ataxia Type 17
- ARCA1 - Autosomal Recessive Cerebellar Ataxia Type 1

## Interventions

- **DRUG:** CAD-1883
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04301284
- **Lead sponsor:** Cadent Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-06
- **Primary completion:** 2022-11
- **Final completion:** 2022-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** In January 2021 Novartis acquired Cadent Therapeutics. As part of a pipeline reassessment, the Synchrony-1 trial will not proceed as initially scheduled.
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04301284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04301284, "Study of CAD-1883 for Spinocerebellar Ataxia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04301284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*